Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.46 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5236823 | 1.00 | CHRM5 (0.47) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL7977009 | 1.00 | CHRM5 (0.47) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL8772735 | 0.84 | GBA1 (0.46) | MAOBHTR1ASIGMAR1GBA1CCR3 | |
| SCHEMBL13215737 | 0.82 | HTT (0.47) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL5239977 | 0.82 | TAAR1 (0.45) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2933979 | 0.82 | GBA1 (0.44) | MAOBHTR1ASIGMAR1CYP19A1GBA1 | |
| SCHEMBL6261865 | 0.81 | GBA1 (0.46) | SIGMAR1CYP19A1GBA1CCR3GRIN2B | |
| SCHEMBL4701393 | 0.80 | ALDH1A1 (0.45) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL4392777 | 0.78 | TAAR1 (0.48) | TAAR1 | |
| SCHEMBL11310048 | 0.77 | EED (0.50) | LTB4RLTB4R2HTR1ACYP19A1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7153983-B2 | Chemo-enzymatic process for the preparation of opticaly enriched β-benzyl-γ-butyrolactones | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-12-26 | — | — | US | claimed |
| US-20040014993-A1 | Novel chemo-enzymatic process for the preparation of opticaly enriched beta-benzyl-gamma-butyrolactones | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2004-01-22 | — | — | US | claimed |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
| CN-110563672-B | Method for preparing 4-bit chiral substituted gamma-butyrolactone | 江苏恒盛药业有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-110563672-A | Method for preparing 4-bit chiral substituted gamma-butyrolactone | 江苏恒盛药业有限公司 | 2019-12-13 | — | — | CN | disclosed |
| US-20180170918-A1 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | CAYMAN CHEMICAL CO INC (US) | 2018-06-21 | — | — | US | disclosed |
| US-9914725-B2 | Methods of synthesizing a difluorolactam analog | CAYMAN CHEMICAL COMPANY, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-9427440-B2 | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-30 | — | — | US | disclosed |
| US-9346825-B2 | Fused bicyclic oxazolidinone CETP inhibitor | MERCK SHARP & DOHME CORP. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160060253-A1 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | CAYMAN CHEMICAL COMPANY, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20140107101-A1 | Macrocyclic Indole Derivatives Useful as Hepatitis C Virus Inhibitors | JANSSEN R&D IRELAND (IL) | 2014-04-17 | — | — | US | disclosed |
| US-20130109649-A1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | MERCK SHARP & DOHME LLC | 2013-05-02 | — | — | US | disclosed |
| US-8242174-B2 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA LLC (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120157462-A1 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA, LLC | 2012-06-21 | — | — | US | disclosed |
| US-20110105473-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2011-05-05 | — | — | US | disclosed |
| US-7153983-B2 | Chemo-enzymatic process for the preparation of opticaly enriched β-benzyl-γ-butyrolactones | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-12-26 | — | — | US | disclosed |
| US-7153983-B2 | Chemo-enzymatic process for the preparation of opticaly enriched β-benzyl-γ-butyrolactones | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-12-26 | — | — | US | disclosed |
| US-20040014993-A1 | Novel chemo-enzymatic process for the preparation of opticaly enriched beta-benzyl-gamma-butyrolactones | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2004-01-22 | — | — | US | disclosed |
| US-20040014993-A1 | Novel chemo-enzymatic process for the preparation of opticaly enriched beta-benzyl-gamma-butyrolactones | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014993-A1 | Novel chemo-enzymatic process for the preparation of opticaly enriched beta-benzyl-gamma-butyrolactones | BBOX1, BCHE, AOX1 | CHRM5 593/4885CHRM2 359/4885CHRM4 415/4885 |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | SPPL2A, SPPL2B, BACE1 | CHRM5 4420/4885CHRM2 3520/4885CHRM4 4423/4885 |
| US-20110105473-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | IDO1, HCCS, CCNI | CHRM5 822/4885CHRM2 432/4885CHRM4 1058/4885 |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | CHRM5 2347/4885CHRM2 1396/4885CHRM4 1724/4885 |
| US-20140107101-A1 | Macrocyclic Indole Derivatives Useful as Hepatitis C Virus Inhibitors | IDO1, HCCS, CCNI | CHRM5 822/4885CHRM2 432/4885CHRM4 1058/4885 |
| US-20120157462-A1 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | ANTXR2, AGXT, AADAC | CHRM5 3873/4885CHRM2 3578/4885CHRM4 4247/4885 |
| US-20180170918-A1 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | PTGER4, PTGER1, PTGIR | CHRM5 107/4885CHRM2 49/4885CHRM4 31/4885 |
| US-20130109649-A1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | CETP, MTTP, APOB | CHRM5 4879/4885CHRM2 4877/4885CHRM4 4864/4885 |
| US-20160060253-A1 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | PTGER4, PTGER1, PTGIR | CHRM5 107/4885CHRM2 49/4885CHRM4 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.